Exenatide Completed Phase 4 Trials for Type 2 Diabetes Mellitus / Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD Treatment

Back to Exenatide

Indications	Status	Purpose	Phase
DBCOND0029752 (Type 2 Diabetes Mellitus) DBCOND0050561 (Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD)	Completed	Treatment	4

clinicaltrials.gov Identifier	Title	Drugs
NCT02303730	Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes	Exenatide (DB01276) Insulin glargine (DB00047)
NCT01006889	Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease	Exenatide (DB01276)